Squire Patton Boggs Advises on Sale of Global Healthcare Communications Consultancy 90TEN

    View Contact / News /London

    Squire Patton Boggs has advised the shareholders of 90TEN, a global independent healthcare communications consultancy, on the sale of the company to Envision Pharma Group, a global provider of evidence-based communication services and industry-leading technology solutions.

    The Squire Patton Boggs multi-practice team was led by Corporate partner Mark Yeo in London, along with senior associate Joe Abbott and associate Lauren Thomas.

    90TEN is a global independent healthcare communications consultancy. Founded in 2001 by Carole North and Paul Tanner, 90TEN has grown into a global behavioral science-led communications group with capabilities in public relations, medical education and patient advocacy. 90TEN is the recipient of over 50 industry awards.

    Also founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions that have applicability across many areas of medical affairs and related functional responsibility. Envision Pharma Group provides services and technology solutions to more than 90 companies, including all of the top 20 pharmaceutical companies. The company has 14 offices, in the UK, Serbia, Hungary, US, Japan and Australia, employing around 800 people.

    The acquisition was supported by Envision’s equity partners, Ardian, one of the largest European-headquartered private investment funds, and the specialist investor in European healthcare, GHO Capital.

    Press Contacts

    Angelo Kakolyris +1 973 848 5621